Header

BUY LIFE SCIENCE REPORTS

PharmaVision offers a comprehensive choice of high quality, insightful reports which identify key trends, future innovations, and growth opportunities. Our reports cover the life science arena including pharmaceuticals, healthcare, diagnostics, drug delivery, emerging R&D technologies and consumer nutrition.

FEATURED REPORT

Featured Reports Icon

Orphan Drugs: Rescue From the Patent Cliff

2014 has set off to a strong start with some new product approvals and major acquisitions hitting the headlines and leaving investors asking what and who will be next? GSK has been granted FDA Breakthrough Therapy designation for Tafinlar (dabrafenib) in NSCLC and Gilead Science have submitted Idelalisib file for the treatment of refractory NHL. Merck has initiated a rolling submission for MK-3475, an anti PD-1 immunotherapy in advanced melanoma. For more information on new and innovative approaches in orphan drug development see our featured report Orphan Drugs: Rescue From the Patent Cliff.

FREE WHITE PAPER

Free White Paper

Antibody Drug Conjugates

Antibody Drug Conjugates or ADCs are a new class of therapeutic agents that combine the advantages of potent cytotoxic agents with selective targeting of a monoclonal antibody. Two ADCs have been approved Seattle Genomics/Takeda’s Adcetris (2011) and Roche’s Kadcyla (2013) - this has stimulated considerable investment in the field.

EVENTS 2014

Events Icon

3rd Annual conference and EXPO of AnalytiX-2014

18th Apr 2014